Asset Details
Do you wish to reserve the book?
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Do you wish to request the book?
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
2019
Overview
KRAS mutations occur in ∼35% of colorectal cancers and promote tumor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway. KRAS mutations at codons 12, 13, or 61 are thought to prevent GAP protein-stimulated GTP hydrolysis and render KRAS-mutated colorectal cancers unresponsive to epidermal growth factor receptor (EGFR) inhibitors. We report here that KRAS G13-mutated cancer cells are frequently comutated with NF1 GAP but NF1 is rarely mutated in cancers with KRAS codon 12 or 61 mutations. Neurofibromin protein (encoded by the NF1 gene) hydrolyzes GTP directly in complex with KRAS G13D, and KRAS G13D-mutated cells can respond to EGFR inhibitors in a neurofibromin-dependent manner. Structures of the wild type and G13D mutant of KRAS in complex with neurofibromin (RasGAP domain) provide the structural basis for neurofibromin-mediated GTP hydrolysis. These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of KRAS G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
Publisher
National Academy of Sciences
Subject
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Codons
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ EGFR
/ Epidermal growth factor receptors
/ ErbB Receptors - antagonists & inhibitors
/ G13D
/ GTPase
/ GTPase-Activating Proteins - metabolism
/ Guanosine Triphosphate - chemistry
/ Guanosine Triphosphate - metabolism
/ Humans
/ Kinases
/ KRAS
/ Mutation
/ Neurofibromin 1 - metabolism
/ Neurofibromin 1 - physiology
/ NF1
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
